Telix Pharmaceuticals Limited

OTC
TLPPF
paper.types.company
Rentabilité sur six mois: -8.06%
Rendement en dividendes: 0%
Secteur: Healthcare

Calendrier des promotions Telix Pharmaceuticals Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR.

plus de détails
Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 10.84 1
P/BV 14.94 1
P/E 170.05 1
Efficacité
Nom Signification Grade
ROA 4.75 1
ROE 12.69 4
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 6.29 0
Debt/Ratio 0.3834 10
Debt/Equity 1.67 7
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 12989.74 10
Rentabilité Ebitda, % -272.78 0
Rentabilité EPS, % -163.78 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 16.05 $ 0 $ 0 $ 3.52 % 0 % 0 %
common.calendar.number_days.7d 16.7 $ 16.05 $ 16.61 $ -0.51 % 0 % 0 %
common.calendar.number_days.30d 16.54 $ 16.03 $ 17.5 $ 0.44 % 0 % 0 %
common.calendar.number_days.90d 16.61 $ 13.25 $ 19.25 $ 0.04 % 0 % 0 %
common.calendar.number_days.180d 18.07 $ 13.25 $ 20.35 $ -8.06 % 0 % 0 %
common.calendar.number_days.1y 12.92 $ 11.21 $ 20.35 $ 28.6 % 0 % 0 %
common.calendar.number_days.3y 4.31 $ 2.75 $ 20.35 $ 285.5 % 0 % 0 %
common.calendar.number_days.5y 0.95 $ 0.95 $ 20.35 $ 1648.95 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.635 $ 20.35 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 17.11 $ 13.25 $ 20.35 $ -2.9 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Darren Smith B.Bus., FCPA, M.B.A. Group Chief Financial Officer 379.52k 1965 (60 années)
Dr. Andreas Kluge M.D., Ph.D. Chief Medical Advisor & Non-Executive Director 28.57k 1965 (60 années)
Mr. Richard Valeix M.B.A. Chief Executive Officer of Telix Therapeutics 424.25k 1975 (50 années)
Mr. Craig Ulrick Chief Information Officer N/A
Ms. Kyahn Williamson B.A. Senior Vice President of Corporate Communications & Investor Relations N/A
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. Senior Vice President of Global Governance, Risk & Compliance N/A
Mr. Darren Patti Group Chief Operating Officer N/A 1972 (53 année)
Dr. David N. Cade M.B.A., M.D., MBBS Group Chief Medical Officer N/A 1969 (56 années)
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA Co-Founder, MD, Group CEO & Executive Director 1976 (49 années)
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) Chief Scientist

Informations sur l'entreprise

Adresse: Australia, North Melbourne. VIC, 55 Flemington Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://telixpharma.com